Jack Zhang leads our work in China. Photo: PATH/Mike Wang.
Program Leader, China
Jiankang (Jack) Zhang, MS, MBA, represents PATH in China. He is responsible for program development, project management, office management, and liaising with local and international collaborators, including local health authorities, public and private institutions, and other nongovernmental organizations in China.
Mr. Zhang joined PATH in January 2007 as senior program officer for commercialization with the Ultra Rice® project in China; he was appointed to program leader later that year. Before joining PATH, he created and served as chief representative and general manager of Haemoneitics China Subsidiary, a Boston-based blood-processing company. Prior to that, Mr. Zhang worked at the Shanghai Institute of Biological Products (SIBP), a subsidiary of China National Biotec Group, where his last position was executive vice president for operations. During his tenure at SIBP, he also served as director of the board of SmithKline Beecham Biologicals (Shanghai) Co., Ltd, and as vice chairman of the board of Shanghai Feilong Medical Diagnostic Articles Ltd., a joint venture between SIBP and the Lab System Company of Finland.
His areas of management experience include strategy, organization building, and business development and commercialization of vaccines, plasma-derived products, diagnostics, and medical devices in transfusion therapy.
Mr. Zhang obtained a diploma in public health from Shanghai Songjiang Health School, a BA in French and English from Shanghai Fudan University, a master of library and information sciences (MLIS) specializing in medicine from a joint program of Dominican University and Loyola Medical School, and an Executive MBA from the China European International Business School.